Therapeutic monitoring of carbamazepine and its active metabolite during the 1st postnatal month: Influence of drug interactions
Language English Country France Media print-electronic
Document type Journal Article
PubMed
33761618
DOI
10.1016/j.biopha.2021.111412
PII: S0753-3322(21)00197-9
Knihovny.cz E-resources
- Keywords
- Breastfeeding, Carbamazepine, Epoxide, Therapeutic drug monitoring,
- MeSH
- Anticonvulsants metabolism pharmacokinetics MeSH
- Biotransformation MeSH
- Adult MeSH
- Enzyme Induction drug effects MeSH
- Epoxy Compounds metabolism MeSH
- Carbamazepine metabolism pharmacokinetics MeSH
- Cohort Studies MeSH
- Breast Feeding MeSH
- Valproic Acid pharmacokinetics MeSH
- Drug Interactions MeSH
- Humans MeSH
- Milk, Human chemistry metabolism MeSH
- Young Adult MeSH
- Drug Monitoring MeSH
- Infant, Newborn MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Infant, Newborn MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Anticonvulsants MeSH
- Epoxy Compounds MeSH
- Carbamazepine MeSH
- Valproic Acid MeSH
OBJECTIVE: To receive information about carbamazepine and its active metabolite 10,11-epoxide transport into mature milk and suckling infants. METHODS: In this cohort study, maternal serum, mature milk, and infant serum carbamazepine and epoxide levels were measured between the 6th and 29th postnatal day (carbamazepine in 1990-2017, epoxide in 1997-2017). Paired maternal serum, infant serum and milk levels were used for the assessment of ratios of this levels. The influence of combined treatment with enzyme-inducing antiepileptic drugs and valproic acid was assessed. Relationship between maternal serum, infant serum, and milk levels was also evaluated. RESULTS: Maternal carbamazepine levels were 1.4-10.4 mg/L, milk 0.5-6.7 mg/L and infant 0.5-2.6 mg/L. Maternal 10,11-epoxide levels were 0.3-5.4 mg/L, milk 0.3-3.7 mg/L and infant 0.3-0.6 mg/L. Highly significant correlations were observed exclusively between milk and maternal serum levels of both carbamazepine and 10,11-epoxide. Concomitant administration of enzyme-inducing antiepileptic drugs significantly increased the maternal apparent oral clearance of carbamazepine by approximately 130%. Carbamazepine combined with valproic acid significantly increased epoxide levels in milk and maternal serum but not in breastfed infants. CONCLUSIONS: In breastfed infants, carbamazepine levels did not reach the lower limit of the therapeutic range used for the general epileptic population, and the majority of epoxide levels were less than the lower limit of quantification. Routine monitoring of carbamazepine in these infants is not compulsory. However, observation of breastfed infants is desirable. If signs of potential adverse reactions are evident, infant serum concentrations should be monitor.
References provided by Crossref.org